Literature DB >> 1929556

Repeated treatment with dithranol induces a tolerance reaction in keratinocytes in vitro.

B Farkas1, B Bonnekoh, G Mahrle.   

Abstract

The hyperproliferative human keratinocyte line (HaCaT) was tested for dithranol tolerance (tachyphylaxis) at the cellular level. At day 4 after seeding, keratinocytes were treated with 0.3 or 1.0 microM dithranol. Data were compared with those from experiments including additional pretreatments with 0.3 microM at day 3, or at days 1 and 3. Protein content, DNA synthesis and protein synthesis (incorporation of 3H-thymidine and 14C-amino acids per protein) were determined at 24, 48 and 72 h after the last drug exposure. Protein content of attached cells decreased in relation to dose and frequency of treatments. Inhibition of DNA and protein synthesis (38.2% and 32.3%, respectively) also occurred 24 h after a single treatment with 0.3 microM dithranol, but was only 18.4% and 9.1% after pretreatment twice with 0.3 microM dithranol. This tolerance reaction in vitro, after repeated dithranol exposure of human keratinocytes, may be explained by a selective loss of drug-sensitive cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1929556     DOI: 10.1007/bf00376624

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  37 in total

1.  UVB radiation further stimulates proliferation in the already hyperproliferative epidermis of the asebia mouse.

Authors:  W R Brown; R D Furukawa; C A Ramsay
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

2.  Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action for this drug.

Authors:  K U Schallreuter; M R Pittelkow
Journal:  Arch Dermatol       Date:  1987-11

3.  Skin toxicity and cellular metabolism: in vitro models.

Authors:  U Reichert
Journal:  Br J Dermatol       Date:  1986-08       Impact factor: 9.302

4.  Autoradiographic in vitro-examination of psoriatic skin before, during and after dithranol treatment.

Authors:  G K Steigleder; H Schumann; K J Lennartz
Journal:  Arch Dermatol Forsch       Date:  1973

5.  Cytokinetic effects of anthralin on psoriatic keratinocytes.

Authors:  H Pullmann; K Enderer; G K Steigleder
Journal:  Br J Dermatol       Date:  1981-08       Impact factor: 9.302

6.  Epidermal cell culture systems in skin pharmacology.

Authors:  M Prunieras; C Delescluse
Journal:  Br J Dermatol       Date:  1984-07       Impact factor: 9.302

7.  Inhibition of DNA replication and repair by anthralin or danthron in cultured human cells.

Authors:  J M Clark; P C Hanawalt
Journal:  J Invest Dermatol       Date:  1982-07       Impact factor: 8.551

8.  Rat liver thioredoxin and thioredoxin reductase: purification and characterization.

Authors:  M Luthman; A Holmgren
Journal:  Biochemistry       Date:  1982-12-21       Impact factor: 3.162

9.  Formation of active oxygen species by dithranol, III. Dithranol, active oxygen species and lipid peroxidation in vivo.

Authors:  K Müller; W Wiegrebe; M Younes
Journal:  Arch Pharm (Weinheim)       Date:  1987-01       Impact factor: 3.751

10.  Incorporation of 3H-thymidine into DNA: inhibition by dithranol and its di- and triacetate.

Authors:  E Plumier; B Wappes; W Wiegrebe
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

View more
  2 in total

Review 1.  Functionally important amino acid residues in the transient receptor potential vanilloid 1 (TRPV1) ion channel--an overview of the current mutational data.

Authors:  Zoltán Winter; Andrea Buhala; Ferenc Ötvös; Katalin Jósvay; Csaba Vizler; György Dombi; Gerda Szakonyi; Zoltán Oláh
Journal:  Mol Pain       Date:  2013-06-22       Impact factor: 3.395

2.  Divalent heavy metal cations block the TRPV1 Ca(2+) channel.

Authors:  László Pecze; Zoltán Winter; Katalin Jósvay; Ferenc Ötvös; Csongor Kolozsi; Csaba Vizler; Dénes Budai; Tamás Letoha; György Dombi; Gerda Szakonyi; Zoltán Oláh
Journal:  Biol Trace Elem Res       Date:  2012-12-21       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.